There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProKidney (PROK – Research Report) and Enliven Therapeutics (ELVN – Research Report) with bullish sentiments.
ProKidney (PROK)
Jefferies analyst Kelly Shi maintained a Buy rating on ProKidney yesterday and set a price target of $15.00. The company’s shares closed last Thursday at $9.02.
According to TipRanks.com, Shi is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on ProKidney is a Moderate Buy with an average price target of $14.00.
See Insiders’ Hot Stocks on TipRanks >>
Enliven Therapeutics (ELVN)
Jefferies analyst Eun Yang maintained a Buy rating on Enliven Therapeutics yesterday and set a price target of $27.00. The company’s shares closed last Thursday at $19.10.
According to TipRanks.com, Yang is a 4-star analyst with an average return of
Enliven Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.00, implying a 59.8% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PROK:
